Aadi Bioscience Financials
AADI Stock | USD 2.30 0.02 0.88% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 3.1 | 4.7201 |
|
|
Investors should never underestimate Aadi Bioscience's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Aadi Bioscience's cash flow, debt, and profitability to make informed and accurate decisions about investing in Aadi Bioscience.
Net Income |
|
Aadi | Select Account or Indicator |
Understanding current and past Aadi Bioscience Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Aadi Bioscience's financial statements are interrelated, with each one affecting the others. For example, an increase in Aadi Bioscience's assets may result in an increase in income on the income statement.
Aadi Bioscience Stock Summary
Aadi Bioscience competes with Anebulo Pharmaceuticals, Adagene, Acrivon Therapeutics,, AnaptysBio, and Mineralys Therapeutics,. Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California. Aadi Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 67 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US00032Q1040 |
CUSIP | 00032Q104 00810B105 |
Location | California; U.S.A |
Business Address | 17383 Sunset Boulevard, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | aadibio.com |
Phone | 424 744 8055 |
Currency | USD - US Dollar |
Aadi Bioscience Key Financial Ratios
Return On Equity | -0.66 | ||||
Profit Margin | (2.46) % | ||||
Operating Margin | (1.49) % | ||||
Price To Sales | 2.24 X | ||||
Revenue | 24.35 M |
Aadi Bioscience Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 39.9M | 18.8M | 157.9M | 184.2M | 132.4M | 139.0M | |
Net Debt | (38.4M) | 5.8M | (148.4M) | (37.4M) | (61.6M) | (58.5M) | |
Retained Earnings | (142.2M) | (32.6M) | (142.7M) | (203.2M) | (269.0M) | (255.5M) | |
Cash | 38.5M | 4.5M | 149.0M | 39.0M | 62.9M | 66.0M | |
Total Current Assets | 39.6M | 18.7M | 151.3M | 180.0M | 124.6M | 130.8M | |
Total Liab | 3.4M | 31.3M | 21.5M | 25.9M | 27.2M | 28.6M | |
Other Current Liab | 2.8M | 99K | 8.7M | 14.5M | 20.1M | 21.1M | |
Accounts Payable | 439.8K | 2.4M | 6.4M | 3.5M | 5.9M | 6.2M | |
Other Current Assets | 1.0M | 81K | 4.6M | 3.7M | 3.8M | 4.0M | |
Net Tangible Assets | (9.1M) | 43.1M | 132.6M | 158.4M | 182.1M | 191.2M |
Aadi Bioscience Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Operating Income | (22.6M) | (2.5M) | (111.2M) | (59.0M) | (71.9M) | (68.3M) | |
Ebit | (22.6M) | (2.7M) | (109.4M) | (60.3M) | (65.5M) | (62.3M) | |
Ebitda | (22.5M) | (2.5M) | (109.1M) | (60.1M) | (65.4M) | (62.1M) | |
Income Before Tax | (23.3M) | (3.5M) | (110.1M) | (60.5M) | (65.8M) | (62.5M) | |
Net Income | (23.3M) | (3.5M) | (110.1M) | (57.0M) | (65.8M) | (62.5M) | |
Interest Expense | 0.0 | 815K | 665K | 230K | 231K | 224.8K | |
Gross Profit | 672.5K | 13.8M | 724K | 13.9M | 21.5M | 22.6M | |
Research Development | 12.8M | 15.0M | 19.7M | 32.7M | 48.9M | 51.4M | |
Income Tax Expense | 778.2K | 1.3K | 2K | (3.5M) | 1.1K | 1.2K | |
Total Revenue | 749K | 14M | 1M | 15.2M | 24.4M | 13.8M |
Aadi Bioscience Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | (24.1M) | (11.5M) | 144.5M | (109.9M) | 23.9M | 25.1M | |
Free Cash Flow | (24.1M) | (12.7M) | (22.5M) | (50.1M) | (63.6M) | (60.5M) | |
Capital Expenditures | 237.0K | 19.0K | 46K | 444K | 4.0M | 4.2M | |
End Period Cash Flow | 38.5M | 4.5M | 149.0M | 39.1M | 63.0M | 66.1M | |
Other Non Cash Items | 3.6M | 982K | 836K | 2.9M | (2.6M) | (2.5M) | |
Net Income | (23.3M) | (3.5M) | (110.1M) | (60.5M) | (65.8M) | (62.5M) | |
Depreciation | 76.5K | 9K | 105K | 159K | 169K | 90.9K | |
Change To Netincome | 301.5K | 1.3M | 2.9M | 12.5M | 14.4M | 15.1M |
Aadi Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Aadi Bioscience's current stock value. Our valuation model uses many indicators to compare Aadi Bioscience value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aadi Bioscience competition to find correlations between indicators driving Aadi Bioscience's intrinsic value. More Info.Aadi Bioscience is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . As of now, Aadi Bioscience's Return On Equity is increasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Aadi Bioscience's earnings, one of the primary drivers of an investment's value.Aadi Bioscience Systematic Risk
Aadi Bioscience's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Aadi Bioscience volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Aadi Bioscience correlated with the market. If Beta is less than 0 Aadi Bioscience generally moves in the opposite direction as compared to the market. If Aadi Bioscience Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Aadi Bioscience is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Aadi Bioscience is generally in the same direction as the market. If Beta > 1 Aadi Bioscience moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Aadi Bioscience Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Aadi Bioscience's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Aadi Bioscience growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Aadi Bioscience November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Aadi Bioscience help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Aadi Bioscience. We use our internally-developed statistical techniques to arrive at the intrinsic value of Aadi Bioscience based on widely used predictive technical indicators. In general, we focus on analyzing Aadi Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Aadi Bioscience's daily price indicators and compare them against related drivers.
Downside Deviation | 2.8 | |||
Information Ratio | 0.1787 | |||
Maximum Drawdown | 17.97 | |||
Value At Risk | (3.87) | |||
Potential Upside | 5.46 |
Complementary Tools for Aadi Stock analysis
When running Aadi Bioscience's price analysis, check to measure Aadi Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aadi Bioscience is operating at the current time. Most of Aadi Bioscience's value examination focuses on studying past and present price action to predict the probability of Aadi Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aadi Bioscience's price. Additionally, you may evaluate how the addition of Aadi Bioscience to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data |